<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626912</url>
  </required_header>
  <id_info>
    <org_study_id>ND07.001</org_study_id>
    <nct_id>NCT00626912</nct_id>
  </id_info>
  <brief_title>PRET: Patients Prone to Recurrence After Endovascular Treatment</brief_title>
  <acronym>PRET</acronym>
  <official_title>PRET: Patients Prone to Recurrence After Endovascular Treatment. A Randomized Trial Comparing Platinum and Hydrogel-coated Coils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PRET study aims at comparing two types of coils used in the endovascular treatment of
      intracranial aneurysms. The first type made of platinum has been used for more than 15 years.
      The other, referred to as hydrocoil, containing in addition to platinum a polymer layer that
      expands when in contact with blood, has been in use since 2002. The hypothesis of the PRET
      study is that the newer hydrocoil will be more effective and yet as safe as the older
      platinum coil.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Rate of Target Aneurysm.</measure>
    <time_frame>18 months</time_frame>
    <description>major angiographic recurrence of the lesion or the presence of a residual aneurysm at last angiographic follow-up, as determined by the core laboratory, blinded to treatment allocation;
retreatment of the same aneurysm by endovascular or surgical means during the 18-month follow-up period;
an intracranial bleeding episode, or the occurrence or progression of a mass effect in relation to the treated aneurysm during the follow-up period, as determined by the blinded Adverse Event Committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants dead - All causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants having experienced one or several Adverse Events. This measure is the number of participants having experienced Serious Adverse Events plus those having experienced other (not including Serious) Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants having experienced one or several Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">447</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>platinum coils</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hydrogel coils</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular coil embolization</intervention_name>
    <description>standard endovascular coil embolization with or without adjunct techniques</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>platinum coil</other_name>
    <other_name>hydrogel coil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting at least one aneurysm 'prone to recurrence after endovascular
             treatment' (PRET), defined for the sake of this study as:

               -  PRET-1: One ruptured or unruptured aneurysm, never treated, with a dimension
                  ≥10mm (longest axis, including thrombosed portions of large or giant aneurysms);
                  for ruptured lesions, patients should be in WFNS grade I, II or III.

               -  PRET-2: an Aneurysm presenting a major recurrence after previous coiling; and
                  judged by the neurovascular team to require elective treatment.

          -  The anatomy of the lesion is such that endovascular treatment is possible with both
             types of coils (not necessarily certain or probable)

          -  The endovascular physician is content to use either type of coils (platinum or
             hydrogel-coated coils) but no other type of coils

          -  Patient is 18 or older

          -  Life expectancy is more than 2 years

        Exclusion Criteria:

          -  Presence of other aneurysms requiring treatment during the same session

          -  Patients with associated cerebral arteriovenous malformations

          -  When parent vessel occlusion, without simultaneous endosaccular coiling of the
             aneurysm, is the primary intent of the procedure

          -  Any absolute contraindication to endovascular treatment, angiography, or anaesthesia
             such as severe allergies to contrast or medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean RAYMOND, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel ROY, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shands - University of Florida Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississipi Health Care</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Cape Girardeau</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Buffalo (SUNY)</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center (SUNY)</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal - Notre Dame Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurocirugía Dr. Asenjo</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor - Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy-Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôpital Guillaume et René Laennec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte Anne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Walton Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham,</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.iconetwork.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>February 21, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>August 1, 2017</results_first_submitted>
  <results_first_submitted_qc>October 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2019</results_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>large aneurysm</keyword>
  <keyword>recurrence</keyword>
  <keyword>hydrocoil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Platinum Coils</title>
          <description>Endovascular coil embolization with standard platinum coils</description>
        </group>
        <group group_id="P2">
          <title>Hydrogel Coils</title>
          <description>Endovascular Coil embolization with Hydrogel Coils</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Platinum Coils</title>
          <description>Endovascular coil embolization with standard platinum coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
        </group>
        <group group_id="B2">
          <title>Hydrogel Coils</title>
          <description>Endovascular coil embolization with hydrogel coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="222"/>
            <count group_id="B2" value="225"/>
            <count group_id="B3" value="447"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="12"/>
                    <measurement group_id="B2" value="57" spread="11"/>
                    <measurement group_id="B3" value="58" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="319"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ruptured aneurysms (Number)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aneurysm size (mean (SD))</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="222"/>
                    <count group_id="B2" value="225"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.3" spread="5.8"/>
                    <measurement group_id="B2" value="10.7" spread="5.3"/>
                    <measurement group_id="B3" value="11.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence Rate of Target Aneurysm.</title>
        <description>major angiographic recurrence of the lesion or the presence of a residual aneurysm at last angiographic follow-up, as determined by the core laboratory, blinded to treatment allocation;
retreatment of the same aneurysm by endovascular or surgical means during the 18-month follow-up period;
an intracranial bleeding episode, or the occurrence or progression of a mass effect in relation to the treated aneurysm during the follow-up period, as determined by the blinded Adverse Event Committee.</description>
        <time_frame>18 months</time_frame>
        <population>For the Platinum coils population (222):
Primary outcome available for 220/222 (could not attribute primary outcome for 2 participants)
For the Hydrogel coils population (225):
Withdrawn by physician right after Registration: 3/225 (remaining 222) Primary outcome available for 215/222 (could not attribute primary outcome for 7 participants)</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum Coils</title>
            <description>platinum coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
          </group>
          <group group_id="O2">
            <title>Hydrogel Coils</title>
            <description>hydrogel coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Rate of Target Aneurysm.</title>
          <description>major angiographic recurrence of the lesion or the presence of a residual aneurysm at last angiographic follow-up, as determined by the core laboratory, blinded to treatment allocation;
retreatment of the same aneurysm by endovascular or surgical means during the 18-month follow-up period;
an intracranial bleeding episode, or the occurrence or progression of a mass effect in relation to the treated aneurysm during the follow-up period, as determined by the blinded Adverse Event Committee.</description>
          <population>For the Platinum coils population (222):
Primary outcome available for 220/222 (could not attribute primary outcome for 2 participants)
For the Hydrogel coils population (225):
Withdrawn by physician right after Registration: 3/225 (remaining 222) Primary outcome available for 215/222 (could not attribute primary outcome for 7 participants)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Rate</title>
        <description>Number of participants dead - All causes</description>
        <time_frame>18 months</time_frame>
        <population>For the Platinum coils population (222):
Secondary outcome measure applies to 222 participants.
For the Hydrogel coils population (225):
Withdrawn by physician right after Registration: 3/225 (remaining 222). Secondary outcome measure applies to 222 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum Coils</title>
            <description>platinum coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
          </group>
          <group group_id="O2">
            <title>Hydrogel Coils</title>
            <description>hydrogel coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate</title>
          <description>Number of participants dead - All causes</description>
          <population>For the Platinum coils population (222):
Secondary outcome measure applies to 222 participants.
For the Hydrogel coils population (225):
Withdrawn by physician right after Registration: 3/225 (remaining 222). Secondary outcome measure applies to 222 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of participants having experienced one or several Adverse Events. This measure is the number of participants having experienced Serious Adverse Events plus those having experienced other (not including Serious) Adverse Events.</description>
        <time_frame>18 months</time_frame>
        <population>For the Platinum coils population (222):
Secondary outcome measure applies to 222 participants.
For the Hydrogel coils population (225):
Withdrawn by physician right after Registration: 3/225 (remaining 222). Secondary outcome measure applies to 222 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum Coils</title>
            <description>platinum coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
          </group>
          <group group_id="O2">
            <title>Hydrogel Coils</title>
            <description>hydrogel coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of participants having experienced one or several Adverse Events. This measure is the number of participants having experienced Serious Adverse Events plus those having experienced other (not including Serious) Adverse Events.</description>
          <population>For the Platinum coils population (222):
Secondary outcome measure applies to 222 participants.
For the Hydrogel coils population (225):
Withdrawn by physician right after Registration: 3/225 (remaining 222). Secondary outcome measure applies to 222 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>Number of participants having experienced one or several Serious Adverse Events</description>
        <time_frame>18 months</time_frame>
        <population>For the Platinum coils population (222):
Secondary outcome measure applies to 222 participants.
For the Hydrogel coils population (225):
Withdrawn by physician right after Registration: 3/225 (remaining 222). Secondary outcome measure applies to 222 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum Coils</title>
            <description>platinum coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
          </group>
          <group group_id="O2">
            <title>Hydrogel Coils</title>
            <description>hydrogel coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>Number of participants having experienced one or several Serious Adverse Events</description>
          <population>For the Platinum coils population (222):
Secondary outcome measure applies to 222 participants.
For the Hydrogel coils population (225):
Withdrawn by physician right after Registration: 3/225 (remaining 222). Secondary outcome measure applies to 222 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>an Adverse Event is defined as an event of any severity being possibly or probably related to the disease or the treatment and happening at any time during the 18-month follow-up period. The independent Adverse Event Committee was responsible for the attribution of Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Platinum Coils</title>
          <description>platinum coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
        </group>
        <group group_id="E2">
          <title>Hydrogel Coils</title>
          <description>hydrogel coils
endovascular coil embolization: standard endovascular coil embolization with or without adjunct techniques</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Retreatment related</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>periprocedure event</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>sub-arachnoid hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Mass Effect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>subdural hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>non neurologic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Retreatment related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Periprocedure event</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Mass Effect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Inflammatory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Non neurologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Operators could not be blinded to coil type. This may have affected case selection, coil selection, and completeness of the coiling procedure. Aneurysm volumes were not directly measured but extrapolated from aneurysm dimensions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ruby Klink, coordinator</name_or_title>
      <organization>Centre de Recherches du Centre Hospitalier de l'Université de Montréal</organization>
      <phone>(514) 890 8000 ext 25245</phone>
      <email>ruby.klink@crchum.qc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

